Earnings before interest and tax and net profit were up 21%, at $263m and $185m respectively.
Basic earnings a share were 25.15c but the company will continue its policy of not paying a dividend while reinvesting its profits.
A2 had a closing cash balance on December 31 of $618.4m, up $154m on the June 30, 2019, number.
Products for infant nutrition accounted for 82% of the revenue and liquid milk sales 13%.
The sales of a2 Platinum Chinese-label infant nutrition products through 18,000 stores were $146m, double those of the previous corresponding period.
Cross-border e-commerce sales were of similar size at $159m.
The share of infant nutrition sales in Australian grocery and pharmacy channels has fallen to 54% of the total, showing a steady conversion rate of daigou sales into in-store and e-channel sales in China.
Sales of liquid milk in the United States also doubled, to revenue of $28m, and liquid milk sales in Australia rose 11% to $75m.
A2 milk accounts for 11% of all milk sales in Australia.
The company says it has a near-term goal of reaching US$100m of annual sales in the US and it has expanded distribution to 17,500 stores.
It produces four milk varieties and two coffee creamers.
A2 directors said it is time to assess participation in infant nutrition manufacturing facilities to complement existing supply chain relationships.
Acting chief executive Geoff Babidge said the company expects strong revenue growth to continue in the second half-year but it is hard to assess the impact of coronavirus, either positively or negatively.
The company might increase marketing in China for the rest of the fiscal year.
The share price reacted positively, putting on $1 or about 7%, to be around $16.70.
